WO2008022006A3 - Arylalkoxyl hepatitis c virus protease inhibitors - Google Patents
Arylalkoxyl hepatitis c virus protease inhibitors Download PDFInfo
- Publication number
- WO2008022006A3 WO2008022006A3 PCT/US2007/075653 US2007075653W WO2008022006A3 WO 2008022006 A3 WO2008022006 A3 WO 2008022006A3 US 2007075653 W US2007075653 W US 2007075653W WO 2008022006 A3 WO2008022006 A3 WO 2008022006A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hepatitis
- present
- subject
- virus
- arylalkoxyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50341306A | 2006-08-11 | 2006-08-11 | |
US11/503,413 | 2006-08-11 | ||
US11/836,288 US7687459B2 (en) | 2006-08-11 | 2007-08-09 | Arylalkoxyl hepatitis C virus protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008022006A2 WO2008022006A2 (en) | 2008-02-21 |
WO2008022006A3 true WO2008022006A3 (en) | 2008-10-30 |
Family
ID=39082988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/075653 WO2008022006A2 (en) | 2006-08-11 | 2007-08-10 | Arylalkoxyl hepatitis c virus protease inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008022006A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8877929B2 (en) | 2008-09-04 | 2014-11-04 | Bristol-Myers Squibb Company | Process for synthesizing substituted isoquinolines |
US8889871B2 (en) | 2002-05-20 | 2014-11-18 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8993595B2 (en) | 2009-04-08 | 2015-03-31 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2624333A1 (en) | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
KR20090024834A (en) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Novel inhibitors of hepatitis c virus replication |
US20080107623A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
CN101580535B (en) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | Hcv protease inhibitors |
UY32099A (en) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS |
CA2761650C (en) | 2009-05-13 | 2015-05-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
CN102020698B (en) * | 2009-09-15 | 2012-08-29 | 太景生物科技股份有限公司 | Hepatitis c virus protease inhibitor |
DK2477980T3 (en) * | 2009-09-15 | 2016-09-12 | Taigen Biotechnology Co Ltd | HCV protease inhibitors |
MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
EA201390988A1 (en) | 2010-12-30 | 2014-04-30 | Энанта Фармасьютикалз, Инк. | PHENANTRIDINE MACROCYCLIC INHIBITORS OF THE HYPATITIS C VIRUS SERIN PROTEASE |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
DE202012013111U1 (en) | 2011-10-21 | 2015-01-14 | Abbvie Inc. | A combination of at least two direct-acting antiviral agents for use in the treatment of HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
SE1450131A1 (en) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA combination therapy (eg with ABT-072 or ABT-333) for use in the treatment of HCV |
CN104918941A (en) | 2012-10-19 | 2015-09-16 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
CN109689063A (en) | 2016-04-28 | 2019-04-26 | 埃默里大学 | Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000009543A2 (en) * | 1998-08-10 | 2000-02-24 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
-
2007
- 2007-08-10 WO PCT/US2007/075653 patent/WO2008022006A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000009543A2 (en) * | 1998-08-10 | 2000-02-24 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8889871B2 (en) | 2002-05-20 | 2014-11-18 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8877929B2 (en) | 2008-09-04 | 2014-11-04 | Bristol-Myers Squibb Company | Process for synthesizing substituted isoquinolines |
US8993595B2 (en) | 2009-04-08 | 2015-03-31 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9527885B2 (en) | 2011-05-05 | 2016-12-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2008022006A2 (en) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors | |
WO2007143694A3 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
WO2008021960A3 (en) | Triazolyl macrocyclic hepatitis c serine protease inhibitors | |
WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
WO2008019289A3 (en) | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors | |
WO2008019303A3 (en) | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors | |
WO2008021733A3 (en) | Tetrazolyl acyclic hepatitis c serine protease inhibitors | |
MX2010005262A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors. | |
MX2010006209A (en) | Quinoxalinyl derivatives. | |
WO2009053828A3 (en) | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors | |
MX2010005261A (en) | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors. | |
MX2010006518A (en) | Macrocyclic oximyl hepatitis c serine protease inhibitors. | |
WO2008002924A3 (en) | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors | |
WO2009076173A3 (en) | Fluorinated tripeptide hcv serine protease inhibitors | |
MX2010010276A (en) | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors. | |
WO2011049908A3 (en) | Bismacrokyclic compounds as hepatitis c virus inhibitors | |
WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
MX2011012155A (en) | Macrocyclic compounds as hepatitis c virus inhibitors. | |
WO2004093798A3 (en) | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors | |
MX2019013037A (en) | Macrocyclic proline derived hcv serine protease inhibitors. | |
WO2009085978A8 (en) | Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors | |
WO2005007681A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07800078 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07800078 Country of ref document: EP Kind code of ref document: A2 |